Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
- PMID: 12727831
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
Abstract
The phosphatidylinositol 3'-kinase/Akt pathway is activated frequently in human cancer, and has been implicated in tumor proliferation, cell survival, and resistance to apoptotic stimuli. Akt forms a complex with heat shock protein (Hsp) 90 and Cdc37, and inhibitors of Hsp90 cause Akt degradation. 17-allylamino-17-demethoxygeldanamycin (17-AGG) is an Hsp90 inhibitor currently in Phase I clinical trial. 17-AAG inhibits Akt activation and expression in tumors, and has antitumor activity in breast cancer xenografts. The combination of 17-AAG and Taxol is synergistic, and 17-AAG sensitizes tumor cells to Taxol-induced apoptosis in a schedule-dependent manner. Transfection of membrane-bound p110 PI3k prevented 17-AAG inactivation of Akt and abrogated the enhancement of Taxol-induced apoptosis caused by the drug. 17-AAG and Taxol could be administered together at their maximally tolerated doses to tumor-bearing mice. Doses of 17-AAG that induce HER2 degradation and cause Akt inactivation but have no single agent activity were effective in sensitizing tumors to Taxol. Enhancement was schedule-dependent and maximal when Taxol and 17-AAG were administered on the same day. These results suggest that Hsp90 inhibitors can effectively suppress Akt activity in animal models of human cancer at nontoxic doses, thus sensitizing tumor cells to proapoptotic stimuli.
Similar articles
-
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.Cancer Res. 2002 Jun 1;62(11):3132-7. Cancer Res. 2002. PMID: 12036925
-
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.Clin Cancer Res. 2006 Jan 15;12(2):584-90. doi: 10.1158/1078-0432.CCR-05-1194. Clin Cancer Res. 2006. PMID: 16428504
-
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.Clin Cancer Res. 2001 Aug;7(8):2228-36. Clin Cancer Res. 2001. PMID: 11489796
-
Hsp90: an emerging target for breast cancer therapy.Anticancer Drugs. 2004 Aug;15(7):651-62. doi: 10.1097/01.cad.0000136876.11928.be. Anticancer Drugs. 2004. PMID: 15269596 Review.
-
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.Future Oncol. 2005 Apr;1(2):273-81. doi: 10.1517/14796694.1.2.273. Future Oncol. 2005. PMID: 16555999 Review.
Cited by
-
Akt Is Controlled by Bag5 through a Monoubiquitination to Polyubiquitination Switch.Int J Mol Sci. 2023 Dec 15;24(24):17531. doi: 10.3390/ijms242417531. Int J Mol Sci. 2023. PMID: 38139359 Free PMC article.
-
Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.Mol Cancer Ther. 2012 Oct;11(10):2233-42. doi: 10.1158/1535-7163.MCT-11-0987. Epub 2012 Aug 14. Mol Cancer Ther. 2012. PMID: 22896668 Free PMC article.
-
Targeting multiple signal transduction pathways through inhibition of Hsp90.J Mol Med (Berl). 2004 Aug;82(8):488-99. doi: 10.1007/s00109-004-0549-9. Epub 2004 May 27. J Mol Med (Berl). 2004. PMID: 15168026 Review.
-
A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. Clin Cancer Res. 2011. PMID: 21349995 Free PMC article.
-
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.Clin Cancer Res. 2020 Oct 1;26(19):5178-5187. doi: 10.1158/1078-0432.CCR-19-3704. Epub 2020 May 4. Clin Cancer Res. 2020. PMID: 32366671 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous